In Nov. 2022, the U.S. nonprofit Multidisciplinary Affiliation for Psychedelic research (MAPS) announced that it had concluded a second period-a few trial on MDMA as a treatment for PTSD—a move commonly found as the https://psychedelicmushroomstores.com/product-category/microdose-capsules/